New Data from Yale University Cancer Center Illuminate Research in Non-Small Cell Lung Cancer (Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition).

Předmět:	IPILIMUMAB NON-small-cell lung carcinoma NIVOLUMAB
Zdroj:	Immunotherapy Weekly; 6/20/2023, p629-629, 1p
Abstrakt:	Keywords: Biotechnology; Cancer; Drugs and Therapies; Health and Medicine; Immunologic Agents; Immunotherapy; Ipilimumab Therapy; Lung Cancer; Lung Diseases and Conditions; Lung Neoplasms; Monoclonal Antibodies; Nivolumab Therapy; Non-Small Cell Lung Cancer; Oncology; Pharmaceuticals; Yervoy Therapy EN Biotechnology Cancer Drugs and Therapies Health and Medicine Immunologic Agents Immunotherapy Ipilimumab Therapy Lung Cancer Lung Diseases and Conditions Lung Neoplasms Monoclonal Antibodies Nivolumab Therapy Non-Small Cell Lung Cancer Oncology Pharmaceuticals Yervoy Therapy 629 629 1 06/19/23 20230620 NES 230620 2023 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on non-small cell lung cancer is the subject of a new report. According to the news reporters, the research concluded: "Combination immunotherapy with nivolumab and ipilimumab does not overcome primary resistance to PD1 axis inhibitor therapy; however, can overcome acquired resistance to PD1 axis inhibitor therapy. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu